Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187242 | 0.76 | — | — | |
| SCHEMBL23084550 | 0.74 | NPC1 (0.30) | SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL11112029 | 0.72 | PDE4B (0.35) | — | |
| SCHEMBL588750 | 0.71 | NPC1 (0.35) | SMN1; SMN2KMT2ANPC1MAPTRAB9A | |
| SCHEMBL23068559 | 0.71 | — | — | |
| SCHEMBL2270436 | 0.70 | LMNA (0.41) | SMN1; SMN2LMNACYP1A2PDE4ACYP2C19 | |
| SCHEMBL373987 | 0.70 | CDK1 (0.32) | CYP1A2CYP2C19KMT2AMAPT | |
| SCHEMBL31622413 | 0.70 | — | — | |
| SCHEMBL13638690 | 0.69 | NPC1 (0.35) | SMN1; SMN2KMT2ANPC1MAPTRAB9A | |
| SCHEMBL19624252 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-12 | — | — | US | disclosed |
| US-20200385400-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2020-12-10 | — | — | US | disclosed |
| WO-2019115775-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE5A, PDE4A, PDE7A | SMN1; SMN2 1900/4885LMNA 3148/4885CYP1A2 939/4885 |
| US-20200385400-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE5A, PDE4A, PDE7A | SMN1; SMN2 1900/4885LMNA 3148/4885CYP1A2 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.